ArticleNeurology and therapy2025

Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty.

Gina Ferrazzano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.